ClinicalTrials.gg
RecruitingNCT07222670POSITSUpdated Oct 16, 2026

A Study Assessing Safety, Tolerability, and Efficacy of INNA-051 in Preventing Respiratory Illness Due to Viral Infections in Healthy Adults 18 to 45 Years of Age

A Phase 2 interventional study of INNA-051 and Placebo in Viral Respiratory Infection and Viral Respiratory Illnesses, sponsored by ENA Respiratory Pty Ltd. Recruiting at 6 sites in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by ENA Respiratory Pty Ltd · Phase 2, Interventional, and Prevention

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.
Updated Oct 16, 20261 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
1,100
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

Acute upper and lower respiratory infections are a major public health problem and a leading cause of morbidity and mortality worldwide. The purpose of this trial is to assess the safety of the investigational agent INNA-051, given intranasally, and its potential effectiveness in reducing the occurrence, severity, and/or the duration of illness resulting from respiratory virus infections. The trial will enroll generally healthy adults (age 18 - 45 years) who are at risk for exposure to viral respiratory infection, for example, due to living conditions or occupation. Participants will be treated with INNA-051 or placebo once weekly for 4 weeks (Part A) or 12 weeks (Part B) during the respiratory virus season.

Read the detailed description

Viral respiratory infections are associated with significant morbidity and mortality. The diversity of viruses, along with their propensity for mutation, ignited an interest in host-directed therapies that are effective across a wide range of viral pathogens. Toll-like receptors (TLRs) are potential targets for the development of such agents given their central role in host immune defenses.

INNA-051, a TLR2/6 agonist, is being developed as an intranasal innate immune-boosting prophylactic approach for individuals at risk for symptoms and/or complications resulting from respiratory viral infections due to age, occupation, and/or co-morbidities.

This randomized, double-blind, two-part, placebo-controlled, multicenter, Phase 2a trial is designed to evaluate the safety, tolerability, and efficacy of INNA-051 in generally healthy adult participants (age 18 to 45 years, inclusive) who are at increased risk for exposure to viral respiratory infections.

The primary purpose of Part A of the trial is to assess the safety and tolerability of INNA-051 (bilateral intranasal dry powder) in an outpatient setting compared with placebo. In part A of the trial, INNA-051 will be self-administered once weekly for 4 weeks in an outpatient setting during the respiratory virus season.

The purpose of Part B of the trial is to measure the safety, tolerability, and efficacy of INNA-051 bilateral intranasal dry powder compared with placebo in the prevention of symptomatic clinical illness due to RT-qPCR-confirmed viral respiratory infections. In part B of the trial, INNA-051 will be self-administered once weekly for 12 weeks during the North American respiratory virus season.

02

Conditions studied

  • Viral Respiratory Infection
  • Viral Respiratory Illnesses

Keywords

  • Respiratory virus
  • Viral respiratory infection
  • Viral respiratory illness
  • Prophylaxis
  • Intranasal
  • Viral respiratory disease
03

In context

Lead sponsor

ENA Respiratory Pty Ltd is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • In good general health and without medical, psychiatric, chronic or intermittent health conditions.
  • At risk for exposure to viral respiratory infection, for example, living in crowded housing, university housing, or military barracks, working in a childcare center or caring for a child aged 10 or less, healthcare workers, factory workers, taxi and bus drivers, grocery clerks, and educators or counselors who work in crowded environments or with multiple exposures with different people daily.
  • Agree to use highly effective .

Exclusion criteria

Exclusion Criteria:

  • Presence of Type I or Type II diabetes, asthma or other chronic respiratory condition.
  • History of Human Immunodeficiency (), any history of replicating , and any history of untreated, active .
  • Receipt of product within 90 days or 5 half-lives of the product, whichever is longer.
  • Active clinical signs or symptoms of acute respiratory illness (runny nose, sore throat, fever, etc.).
  • Received a vaccine against Respiratory Syncytial Virus (RSV) within 90 days.
  • Pregnant or lactating women.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,100 participants (estimated)

Study arms

  • Experimental
    INNA-051

    Drug: INNA-051

  • Placebo comparator
    Placebo

    Other: Placebo

Interventions

  • powder nasal spray.

  • OtherPlacebo

    powder nasal spray.

06

What researchers measure

Primary outcomes

  1. Part A - Number of Participants with Treatment-emergent Adverse Events (TEAEs)

    Time frame: Up to 8 weeks

  2. Part A - Percentage of Participants with TEAEs

    Time frame: Up to 8 weeks

  3. Part A - Number of participants with Serious Adverse Events (SAEs)

    Time frame: Up to 8 weeks

  4. Part A - Percentage of Participants with SAEs

    Time frame: Up to 8 weeks

  5. Part A - Number of Participants with Nasal Irritancy Questionnaire Symptoms (iTNSS Questionnaire)

    Time frame: Up to 4 weeks

  6. Part A - Percentage of Participants with Nasal Irritancy Questionnaire Symptoms (iTNSS Questionnaire)

    Time frame: Up to 4 weeks

  7. Part A - Change in White Blood Cell Count from Baseline

    Time frame: Baseline up to 4 weeks

  8. Part A - Change in Platelet Count from Baseline

    Time frame: Baseline up to 4 weeks

  9. Part A - Change in Hemoglobin from Baseline

    Time frame: Baseline up to 4 weeks

  10. Part A - Change in Alanine Transaminase (ALT) from Baseline

    Time frame: Baseline up to 4 weeks

  11. Part A - Change in Bilirubin (Total) from Baseline

    Time frame: Baseline up to 4 weeks

  12. Part A - Change in Bilirubin (Direct) from Baseline

    Time frame: Baseline up to 4 weeks

  13. Part A - Change in Alkaline Phosphatase (ALP) from Baseline

    Time frame: Baseline up to 4 weeks

  14. Part A - Change in Creatinine from Baseline

    Time frame: Baseline up to 4 weeks

  15. Part A - Change in High Sensitivity C-reactive Protein from Baseline

    Time frame: Baseline up to 4 weeks

  16. Part B - Number of Participants with TEAEs

    Time frame: Up to 16 weeks

  17. Part B - Percentage of Participants with TEAEs

    Time frame: Up to 16 weeks

  18. Part B - Number of Participants with SAEs

    Time frame: Up to 16 weeks

  19. Part B - Percentage of Participants with SAEs

    Time frame: Up to 16 weeks

  20. Part B - Number of Participants with Nasal Irritancy Questionnaire Symptoms (iTNSS Questionnaire)

    Time frame: Up to 12 weeks

  21. Part B - Percentage of Participants with Nasal Irritancy Questionnaire Symptoms (iTNSS Questionnaire)

    Time frame: Up to 12 weeks

  22. Part B - Change in White Blood Cell Count from Baseline

    Time frame: Baseline up to 12 weeks

  23. Part B - Change in Platelet Count from Baseline

    Time frame: Baseline up to 12 weeks

  24. Part B - Change in Hemoglobin from Baseline

    Time frame: Baseline up to 12 weeks

  25. Part B - Change in ALT from Baseline

    Time frame: Baseline up to 12 weeks

  26. Part B - Change in Bilirubin (Total) from Baseline

    Time frame: Baseline up to 12 weeks

  27. Part B - Change in Bilirubin (Direct) from Baseline

    Time frame: Baseline up to 12 weeks

  28. Part B - Change in ALP from Baseline

    Time frame: Baseline up to 12 weeks

  29. Part B - Change in Creatinine from Baseline

    Time frame: Baseline up to 12 weeks

  30. Part B - Change in High Sensitivity C-reactive Protein from Baseline

    Time frame: Baseline up to 12 weeks

  31. Part B - Number of Participants with Reverse Transcription Quantitative Polymerase Chain Reaction (RT-qPCR)-confirmed Symptomatic Viral Respiratory Infections

    Time frame: Up to 12 weeks

  32. Part B - Area Under the Curve (AUC) of the Total Respiratory and Systemic Symptom Scores for Participants with RT-qPCR-confirmed Symptomatic Viral Respiratory Infections

    The AUC of the total respiratory and systemic symptom scores will be assessed using the respiratory infection intensity and impact questionnaire (RiiQ) for participants with RT-qPCR-confirmed symptomatic viral respiratory infections.

    Time frame: Up to 12 weeks

Secondary outcomes

  1. Part B - Number of Participants With RT-qPCR-confirmed Symptomatic Viral Respiratory Infections by Pathogen

    Time frame: Up to 12 weeks

  2. Part B - AUC of the Total Respiratory and Systemic Symptom Scores for Participants with RT-qPCR-confirmed Symptomatic Viral Respiratory Infections by Pathogen

    The AUC of the total respiratory and systemic symptom scores will be assessed using the RiiQ for participants with RT-qPCR-confirmed symptomatic viral respiratory infections.

    Time frame: Up to 12 weeks

  3. Part B - Time to Symptom Resolution in Participants with RT-qPCR-confirmed Symptomatic Viral Respiratory Infections

    Time to symptom resolution in participants with RT-qPCR-confirmed symptomatic viral respiratory infections will be measured using the RiiQ.

    Time frame: Up to 12 weeks

  4. Part B - Duration of Infection for Participants with RT-qPCR-confirmed Symptomatic Viral Respiratory Infections

    Duration of Infection for participants with RT-qPCR-confirmed symptomatic viral respiratory infections as assessed by time to undetectable viral load measured by RT-qPCR.

    Time frame: Up to 12 weeks

  5. Part B - Activities of Daily Living in Participants who have RT-qPCR-Confirmed Symptomatic Viral Respiratory Infections (assessed by EuroQol 5-Dimensions 5-Levels questionnaire [EQ-5D-5L])

    Time frame: Up to 12 weeks

07

Study locations

6 of 6 sites recruiting
  • Center for Vaccine Development and Global Health (CVD)
    Baltimore, Maryland 21201, United States
    Recruiting
  • Naval Medical Research Command (NMRC)
    Bethesda, Maryland 20889, United States
    Recruiting
  • University Health Center at the University of Maryland
    College Park, Maryland 20742, United States
    Recruiting
  • Accellacare of Raleigh
    Raleigh, North Carolina 27609, United States
    Recruiting
  • Accellacare of Piedmont HealthCare
    Statesville, North Carolina 28625, United States
    Recruiting
  • Accellacare - Wilmington
    Wilmington, North Carolina 20841, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for Mar 2027, 15 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2025
First posted
Oct 30, 2025
StartActual
Dec 4, 2025
Primary completionEst.
Mar 12, 2027
CompletionEst.
Apr 9, 2027
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • University Health Center at the University of Maryland · College Park, United States
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    1 site added
    Show site
    • University Health Center at the University of Maryland · College Park, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07222670
Lead sponsor
ENA Respiratory Pty Ltd
Responsible party
Sponsor
First posted
Oct 30, 2025
Start date
Dec 4, 2025
Primary completion
Mar 12, 2027 (estimated)
Completion
Apr 9, 2027 (estimated)
Last update
Oct 16, 2026

Study contacts

ENA Respiratory
Contact
clinicaltrials@enarespiratory.com

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: INNA-051

Start the discussion